Trovagene is a molecular diagnostics company headquartered in San Diego, California. The company’s primary focus is to leverage their cell-free DNA molecular diagnostic technology in cancer and other diseases. Trovagene’s proprietary Precision Cancer Monitoring® (PCM) platform measures circulating tumor DNA (ctDNA) in urine or blood, enabling personalized patient care. These “liquid biopsies” represent a new and rapidly growing diagnostic field with the potential to dramatically improve cancer care and usher in an era of precision oncology. Trovagene’s urine and blood-based tests are available to clinicians for the assessment of known driver mutations in lung, pancreatic, colorectal, neuroendocrine cancers, melanoma and histiocytic disorders. Their noninvasive technology allows for the detection of cancer mutations and monitoring changes in tumor dynamics before, during, and after treatment, providing clinically actionable information. Trovagene’s goal is to broadly commercialize their molecular diagnostic technology via direct sales as well as external license agreements and/or collaborations for broadest access for patient care.